Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cephalon |
---|---|
Information provided by: | Cephalon |
ClinicalTrials.gov Identifier: | NCT00712881 |
Evaluate the efficacy and safety of treatment with MYOCET® in combination with Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles, in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer |
Estimated Enrollment: | 120 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
(1) Investigational Product: Experimental |
Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles
MYOCET® (60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH→TH).
|
(2) Comparison Therapy: Active Comparator |
Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles
Free doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) once every 3 weeks for 4 cycles (AC→TH).
|
A multicentre, open-label, randomized, Phase 2 study to evaluate the efficacy and safety of treatment with MYOCET® in combination with cyclophosphamide and trastuzumab versus free doxorubicin in combination with cyclophosphamide, each followed by docetaxel and trastuzumab, in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Main Exclusion Criteria:
The patient:
Contact: Cephalon Contact | 1-877-237-4879 |
Austria | |
Call For Information | Recruiting |
Wien, Austria, A-1140 | |
Contact: Cephalon Contact 1-877-237-4879 | |
Belgium | |
Call For Information | Recruiting |
Bruxelles, Belgium, 1200 | |
Contact: Cephalon Contact 1-877-237-4879 | |
France | |
Call For Information | Recruiting |
Vandoeuvre-Les-Nancy, France, 54511 | |
Contact: Cephalon Contact 1-877-237-4879 | |
Germany | |
Call For Information | Recruiting |
Dusseldorf, Germany, 40225 | |
Contact: Cephalon Contact 1-877-237-4879 | |
Call For Information | Recruiting |
Rheinfelden, Germany, D-79618 | |
Contact: Cephalon Contact 1-877-237-4879 | |
Call For Information | Recruiting |
München, Germany, 80337 | |
Contact: Cephalon Contact 1-877-237-4879 | |
Spain | |
Call For Information | Recruiting |
Lleida, Spain, 25198 | |
Contact: Cephalon Contact 1-877-237-4879 |
Responsible Party: | Cephalon France ( Sponsor's Medical Expert ) |
Study ID Numbers: | C19562/2037/BC/EU, EudraCT number: 2008-000709-12 |
Study First Received: | July 8, 2008 |
Last Updated: | March 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00712881 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency; Belgium: Federal Agency for Medicinal Products and Health Products; Austria: Agency for Health and Food Safety; Germany: Federal Institute for Drugs and Medical Devices; Spain: Spanish Agency of Medicines |
Skin Diseases Immunologic Factors Breast Neoplasms Cyclophosphamide Immunosuppressive Agents Doxorubicin Docetaxel |
Anti-Bacterial Agents Trastuzumab Antineoplastic Agents, Alkylating Antirheumatic Agents Alkylating Agents Breast Diseases |
Molecular Mechanisms of Pharmacological Action Skin Diseases Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Breast Neoplasms Cyclophosphamide Antibiotics, Antineoplastic Immunosuppressive Agents Doxorubicin Pharmacologic Actions |
Docetaxel Neoplasms Neoplasms by Site Therapeutic Uses Myeloablative Agonists Trastuzumab Antineoplastic Agents, Alkylating Antirheumatic Agents Alkylating Agents Breast Diseases |